Vildagliptin
£45.00 10mg
Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.
Dipeptidyl peptidase IV (DPP-IV) inhibitor.
Vildagliptin, also known as LAF237, is a potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin inhibits the inactivation of glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) by DPP-IV, allowing GLP-1 and GIP to potentiate the secretion of insulin and suppress glucagon release in the pancreas. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity in type 2 diabetes.
Please contact us for availability.
Additional information
| Other Names | LAF237 |
|---|---|
| Three Letter Sequence | 1-[2-[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2S-pyrrolidinecarbonitrile |
| Molecular Weight | 303.4 |
| Molecular Formula | C17H25N3O2 |
| Sequence | 1-[2-[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2S-pyrrolidinecarbonitrile |
| Solubility | Soluble in water |
| Appearance | White solid |
| Storage | Store desiccated, frozen and in the dark |
| Purity | 98% by TLC |